Abstract
Myeloid leukemia associated with Down syndrome (ML-DS) is a rare pediatric cancer. Current standard-of-care includes cytotoxic chemotherapy. 10-20% of patients develop relapsed leukemia or have refractory disease. These patients have a 3-year event-free survival less than 21%. Novel therapy options are needed to improve survival in these patients with relapsed or refractory disease. Our transcriptome analysis to identify transmembrane proteins that are overexpressed in ML-DS compared to normal bone marrow specimens revealed DLK1 as one of the topmost modulated targets. We show that DLK1 knockout in ML-DS cells significantly reduced proliferation in vitro and delayed engraftment in vivo. Furthermore, targeting DLK1 via antibody drug conjugates significantly prolonged survival compared to control isotype antibody drug conjugate in patient-derived xenograft models of refractory ML-DS. Taken together, targeting DLK1 may be a novel treatment option for refractory ML-DS patients. Key Points We identified DLK1 as a novel target differentially expressed in myeloid leukemia associated with Down syndrome (ML-DS). DLK1-targeted antibody drug conjugate was effective in curbing leukemia progression in patient-derived xenograft models of refractory ML-DS
All Related Versions
Funding Information
  • Lisa Dean Moseley Foundation
  • Leukemia Research Foundation of Delaware
  • U.S. Department of War (W81XWH-22-1-0981)
  • Nemours Foundation
  • Deutsche Forschungsgemeinschaft (DFG; KL 2374/6-1)
  • Hilfe für krebskranke Kinder Frankfurt
  • Frankfurter Stiftung für krebskranke Kinder
  • Mildred Scheel Career

This publication has 69 references indexed in Scilit: